Johnson & Johnson (J&J) has reported updated results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The bispecific antibody, which targets epidermal growth factor receptor (EGFR) and MET, achieved confirmed response rates of 73 percent in the first-line setting and 44 percent in
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Can SonoThera’s ultrasound platform reshape gene therapy delivery? Find out how its $125M Series B targets DMD, ADPKD, and XLAS with nonviral precision.
Surf begins human trial for ultrasound-based neuromodulation in RA. Can it challenge biologics? Find out what this means for autoimmune therapy access.
Enodia Therapeutics raised €20.7M to advance AI-powered small molecules targeting SEC61 for selective protein degradation. Find out what this could change.
Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.
Ossium Health’s cryopreserved bone marrow is showing early clinical success. Find out how this could disrupt allogeneic transplantation logistics.
Savara names PANTHERx as exclusive pharmacy for MOLBREEVI in autoimmune PAP. Find out what this launch model means for access, adoption, and strategy.
KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.
MRM Health's MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.